» Articles » PMID: 25931584

A Systematic Review of Transfusion-associated Graft-versus-host Disease

Overview
Journal Blood
Publisher Elsevier
Specialty Hematology
Date 2015 May 2
PMID 25931584
Citations 34
Authors
Affiliations
Soon will be listed here.
Abstract

Transfusion-associated graft-versus-host disease (TA-GVHD) is a rare complication of blood transfusion. The clinicolaboratory features of TA-GVHD and the relative contributions of recipient and component factors remain poorly understood. We conducted a systematic review of TA-GVHD reports. The HLA relationship between donor and recipient was classified as D = 0 when no donor antigens were foreign to the recipient vs D ≥ 1 when ≥1 donor antigen disparity occurred. We identified 348 unique cases. Criteria for component irradiation were met in 48.9% of cases (34.5% immune-compromised, 14.4% related-donor), although nonirradiated components were transfused in the vast majority of these (97.6%). Components were typically whole blood and red cells. When reported, component storage duration was ≤10 days in 94%, and 23 (6.6%) were leukoreduced (10 bedside, 2 prestorage, and 11 unknown). Among 84 cases with HLA data available, the category of D = 0 was present in 60 patients (71%) at either HLA class I or II loci and was more common among recipients without traditional indications for component irradiation. These data challenge the historic emphasis on host immune defects in the pathogenesis of TA-GVHD. The dominant mechanism of TA-GVHD in both immunocompetent and compromised hosts is exposure to viable donor lymphocytes not recognized as foreign by, but able to respond against, the recipient.

Citing Articles

Blood Transfusion and Survival of Children, Adolescent, and Young Adult Patients with Osteosarcoma: A Multicenter Retrospective Cohort Study.

Cho S, Fierstein J, Khalaf R, Morrison J, Metts J Cancers (Basel). 2025; 17(1.

PMID: 39796726 PMC: 11719514. DOI: 10.3390/cancers17010097.


Combined Solid Organ Transplant and Transfusion-Associated Graft-Versus-Host Disease in a Lung Transplant Recipient: An Uncertain Culprit With Lethal Complications.

Sindu D, Franz B, Scott I, Ayyad H, Gaines K, McAnally K Case Rep Transplant. 2024; 2024:3034200.

PMID: 39735334 PMC: 11681980. DOI: 10.1155/crit/3034200.


Management of Casualties from Radiation Events.

Dent R Eur Burn J. 2024; 4(4):584-595.

PMID: 39600027 PMC: 11571868. DOI: 10.3390/ebj4040039.


Donor-Specific Blood Transfusion in Lung Transplantation.

Jin X, Pirenne J, Vos R, Hooft C, Kaes J, Van Slambrouck J Transpl Int. 2024; 37:12822.

PMID: 39553536 PMC: 11565953. DOI: 10.3389/ti.2024.12822.


Designing a linear accelerator-based "X irradiation system" for platelet products: an efficient, safe, accessible and cost-effective alternative for conventional X- or gamma irradiators.

Naghinezhad J, Hosseini E, Siavashpour Z, Houshyari M, Khajetash B, Ghasemzadeh M Sci Rep. 2024; 14(1):28363.

PMID: 39550453 PMC: 11569130. DOI: 10.1038/s41598-024-80118-6.